← Back to patent-cliff list
HOV-12020
Tier C — Watch / tradeHOV-12020
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：Updating
Indications (approved)：常染色体显性遗传病合并皮质下梗死和白质脑病
Regional status
US
-
EU
Phase II
2020-12-21
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of HOV-12020?
Approved indications include: 常染色体显性遗传病合并皮质下梗死和白质脑病.
When does the HOV-12020 patent expire?
No public expiry year is available for HOV-12020 yet; this page updates once verified.
How do I get a quote for HOV-12020 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-06